Key result
CGS15943 reduces fibroblast activation in preclinical HF models via atypical adenosine receptor suppression.
Why the study?
Cardiac fibrosis predicts adverse outcomes in heart failure, yet no FDA-approved therapy directly targets fibrotic remodeling in the heart.
Does CGS15943 reduce fibrotic gene expression and fibroblast activation in preclinical models of cardiac fibrosis?
Does CGS15943 reduce fibrotic gene expression and fibroblast activation in preclinical models of cardiac fibrosis?
CGS15943 was identified as a lead antifibrotic compound that reduces cardiac fibrosis by targeting an atypical adenosine receptor-driven Gβγ signaling pathway, establishing a potential new therapeutic target for heart failure.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This study identifies a common signal through which several adenosine receptors can drive cardiac fibroblast activation. By combining human stem-cell models with mechanistic studies and animal experiments, we could connect a screening result to a specific biological pathway that warrants further therapeutic investigation.”
“We wanted a screening platform that would allow for rapid exclusion of any drugs that harmed the heart, not just one that identifies compounds that stopped scarring.”
“These adenosine receptors normally signal through different G-alpha proteins, but here we show that all three were signaling in an unconventional way. That common, unconventional G-beta-gamma signal helps explain why blocking the receptors together had a much stronger antifibrotic effect than targeting them one at a time.”
CGS15943 shows antifibrotic activity in animal HF models; leaves open whether atypical adenosine receptor inhibition merits human trials.
Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration-approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cell (iPSC)-based platform. Through high-throughput screening, we identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF. Mechanistic studies revealed an atypical adenosine receptor (AR)-dependent signaling pathway in which AR subtypes converge on Gβγ (the βγ subunits of heterotrimeric GTP-binding proteins) to activate phosphoinositide 3-kinase (PI3K)-AKT and yes-associated protein (YAP). CGS suppressed this signaling axis, thereby reducing fibrotic gene expression and fibroblast activation. These findings establish AR-driven Gβγ signaling as a potential therapeutic target for cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Cardiac fibrosis in heart failure. CGS15943 (CGS) was evaluated on Fibrotic gene expression and fibroblast activation. CGS15943 suppressed an atypical adenosine receptor-dependent signaling pathway, reducing fibrotic gene expression and fibroblast activation in preclinical models of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: